TAE Life Sciences (TLS), a leader in developing boron neutron capture therapy (BNCT) technology and associated innovative boron target drugs, and Stella Pharma, the pioneering developer of boronophenylalanine (BPA) under the product name, Steboronine®, for BNCT, are pleased to announce a strategic collaboration focused on the development, commercialization and expansion of BNCT using BPA in the United States and European markets.
We are excited to announce that TAE Life Sciences will have a significant presence at the 20th
International Congress on Neutron Capture Therapy (ICNCT), taking place in Krakow, Poland, from June
24 to 28, 2024.
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the formation of its new commercial leadership team, dedicated to driving the company’s expansion across the Americas, APAC (Asia-Pacific) and EMEAI (Europe, Middle East, Africa, and India).
We are thrilled to announce the addition of Dr. Deepak “Dee” Khuntia, M.D., FASTRO, to the esteemed Board of Directors at TAE Life Sciences. Dr. Khuntia’s vast expertise in radiation oncology and his significant contributions to advancing cancer treatment technologies significantly reinforce our company’s dedication to pioneering advancements in the field.
TAE Life Sciences, proudly announces the successful completion of acceptance testing and regulatory registration inspection of its accelerator- based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption.
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.
How BNCT will improve outcomes for the most difficult-to-treat cancers
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.
The team at TAE Life Sciences is thrilled to unveil groundbreaking research that could transform the landscape of cancer care. A recent study, focusing on TAE Life Sciences’ Boronotyrosine (BTS) drug, a novel borylated amino acid analogue, has demonstrated exceptional potential to elevate the effectiveness of BNCT in combating cancer.
